Dietary supplement labeling with "internal inconsistency" is "red flag" -- FDA's Yetley.
This article was originally published in The Tan Sheet
DIETARY SUPPLEMENT LABELS WITH "INTERNAL INCONSISTENCY" WOULD BE A "RED FLAG" attracting FDA's notice, Office of Special Nutritionals Director Elizabeth Yetley, PhD, said at a National Nutritional Foods Association symposium on structure/function claims in Washington, D.C. on Feb. 29. If a product has "a warning that says it's not a drug treatment and a name that implies that it is, then you have an internal inconsistency," Yetley explained.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC